### Learner Notification

**MED Learning Group**

**MedGames! Multi-Cancer Early Detection: Equipping Clinicians to Answer Key Clinical Questions**

**February 17, 2023 – February 17, 2024  
Online**

**Acknowledgement of Financial Commercial Support**

GRAIL, Inc.

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

A picture containing drawing

Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Evaluate key characteristics of multi-cancer early detection technologies, including the relevance of specific plasma-based biomarkers and DNA methylation patterns in cancer.
2. Recognize the importance of clinical data underlying the use of multi-cancer early detection technologies, including the relevance of the concept of positive predictive value in such trials.
3. Assess relevant groups of patients who may be interested in multi-cancer early detection technologies to enable engagement in effective discussions with patients on characteristics of these tests.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Felecia | Beachum | NA |
| Douglas | Cox | NA |
| Daniel | DaSilva | NA |
| Naomi | De Brito | NA |
| Chris | Drury | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| John J. | Russell | Sanofi, GSK, Pfizer, Bayer: Consulting Fees; Sanofi: Speakers Bureau |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)